Status:
COMPLETED
Novel Drugs After Allo-HSCT in Patients With Multiple Myeloma
Lead Sponsor:
Gruppo Italiano Trapianto di Midollo Osseo
Collaborating Sponsors:
Azienda Ospedaliero-Universitaria Careggi
Conditions:
Multiple Myeloma
Stem Cell Transplant
Eligibility:
All Genders
18+ years
Brief Summary
This is a retrospective observational study of epidemiological surveillance, multicenter, non-profit, spontaneous, Italian on patients submitted to allo-HSCT among Italian Transplant Centers GITMO. T...
Detailed Description
This is a retrospective, observational multicenter, non-profit, spontaneous, Italian study organized under the auspices of the Gruppo Italiano Trapianti di Midollo Osseo that involves the principal Ce...
Eligibility Criteria
Inclusion
- Inclusion Criteria Written and signed study informed consent Multiple myeloma Allogeneic transplantation from related - HLA identical Allogeneic transplantation from volunteer unrelated donor allogeneic transplantation from haploidentical related donor Myeloablative or reduced intensity conditioning regimen
- Exclusion Criteria Second or further allogeneic transplant Plasma cell leukemia Non measurable disease
Exclusion
Key Trial Info
Start Date :
December 17 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 31 2023
Estimated Enrollment :
202 Patients enrolled
Trial Details
Trial ID
NCT04506320
Start Date
December 17 2021
End Date
January 31 2023
Last Update
October 5 2023
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliera di Careggi
Florence, Italy
2
Clinica Ematologica - Policlinico Universitario
Udine, Italy